A new head-to-head study reveals tirzepatide achieves 47% more weight loss than semaglutide in people with obesity but without diabetes, highlighting its superior effectiveness and cardiometabolic ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Tirzepatide discontinuation was associated with reduced cardiometabolic benefits especially among patients with body weight ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

Roll out of weight loss drugs in England could be dramatically sped up to millions of working age adults by making use of ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight ...

Injectable drugs like Ozempic and Mounjaro have transformed obesity treatment by mimicking gut hormones. But experts have ...

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

SaveHealth explores the historical trajectory of weight loss drugs, examining their scientific basis, regulatory battles, public reception, and what lies ahead for pharmacotherapy in obesity ...